Cue Biopharma, Inc. (CUE): Total Assets
$42.21M
As of 2025-12-31
$30.71M
As of 2026-06-30
-22.7%
3-year compound annual growth
-15.8%
5-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $42.21M | +31.1% | 2026-03-16, Balance as of period end |
| 2024-12-31 | $32.19M | -47.7% | 2026-03-16, Balance as of period end |
| 2023-12-31 | $61.53M | -32.6% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $91.28M | +9.5% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $83.40M | -16.2% | 2023-03-21, Balance as of period end |
| 2020-12-31 | $99.53M | +39.0% | 2022-03-16, Balance as of period end |
| 2019-12-31 | $71.61M | +57.8% | 2021-03-09, Balance as of period end |
| 2018-12-31 | $45.36M | -32.2% | 2020-03-12, Balance as of period end |
| 2017-12-31 | $66.95M | n/a | 2019-03-14, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | 2025-12-31 | $42.21M | +31.1% |
| Celularity Inc (CELU) | 2025-12-31 | $107.33M | -19.1% |
| Entrada Therapeutics, Inc. (TRDA) | 2025-12-31 | $377.38M | -28.3% |
| Foghorn Therapeutics Inc. (FHTX) | 2025-12-31 | $198.10M | -30.2% |
| Verastem, Inc. (VSTM) | 2025-12-31 | $246.44M | +142.7% |
| Alumis Inc. (ALMS) | 2025-12-31 | $411.94M | +20.8% |
| Zomedica Corp. (ZOMDF) | 2025-12-31 | $127.04M | -38.7% |
| NewAmsterdam Pharma Co N.V. (NAMS) | 2025-12-31 | $769.28M | -11.0% |
| Verrica Pharmaceuticals Inc. (VRCA) | 2025-12-31 | $47.13M | -12.9% |
Compare CUE, CELU, TRDA, FHTX side by side · Screen every company in Pharmaceutical Preparations ↗